Erratum: The genomic architecture of NLRP7 is Alu rich and predisposes to disease-associated large deletions by Reddy, Ramesh et al.
ARTICLE
The genomic architecture of NLRP7 is Alu rich and
predisposes to disease-associated large deletions
This article has been amended since online publication. A corrigendum also appears in this issue
Ramesh Reddy1,2, Ngoc MP Nguyen1,2,15, Guillaume Sarrabay3,15, Maryam Rezaei4, Mayra CG Rivas5,
Aysenur Kavasoglu6, Hakan Berkil7, Alaa Elshafey8, Ebtesam Abdalla9, Kristin P Nunez9, Hélène Dreyfus10,
Merviel Philippe11, Zahra Hadipour12, Asude Durmaz6, Erin E Eaton13, Brittany Schubert9, Volkan Ulker14,
Fatemeh Hadipour12, Fatemeh Ahmadpour4, Isabelle Touitou3, Majid Fardaei4 and Rima Slim*,1,2
NLRP7 is a major gene responsible for recurrent hydatidiform moles. Here, we report 11 novel NLRP7 protein truncating
variants, of which five deletions of more than 1-kb. We analyzed the transcriptional consequences of four variants. We demonstrate
that one large homozygous deletion removes NLRP7 transcription start site and results in the complete absence of its transcripts
in a patient in good health besides her reproductive problem. This observation strengthens existing data on the requirement of
NLRP7 only for female reproduction. We show that two other variants affecting the splice acceptor of exon 6 lead to its in-frame
skipping while another variant affecting the splice donor site of exon 9 leads to an in-frame insertion of 54 amino acids. Our
characterization of the deletion breakpoints demonstrated that most of the breakpoints occurred within Alu repeats and the
deletions were most likely mediated by microhomology events. Our data define a hotspot of Alu instability and deletions in intron
5 with six different breakpoints and rearrangements. Analysis of NLRP7 genomic sequences for repetitive elements demonstrated
that Alu repeats represent 48% of its intronic sequences and these repeats seem to have been inserted into the common NLRP2/7
primate ancestor before its duplication into two genes.
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INTRODUCTION
Hydatidiform mole (HM) is an aberrant human pregnancy character-
ized by abnormal embryonic development, hydropic degeneration of
chorionic villi and excessive trophoblastic proliferation. Hydatidiform
moles affect 1 in 600 pregnancies in western countries,1 but have
higher frequencies in Southern and Asian countries.2 These moles are
mostly sporadic and not recurrent. Recurrent hydatidiform moles
(RHMs) are defined by the occurrence of at least two moles in the
same patient and affects 1.5–9.3% of women with a prior HM.3–7
To date, two genes, NLRP7 and KHDC3L, responsible for RHMs
have been identified.8,9 Studies by several groups and on various
populations demonstrated that NLRP7 is a major gene for RHMs.
NLRP7 pathogenic variants are found in 48–80% of patients with
RHMs depending on populations and patients inclusion criteria.10–15
To date, 48 distinct pathogenic variants observed in recessive state
in NLRP7 have been reported in a total of 131 patients.16 NLRP7 codes
for a NOD-like receptor pyrin containing protein 7 that plays roles in
inflammatory response,17,18 trophoblastic tissue differentiation19,20
and proliferation,20 and is part of the oocyte cortical cytoskeleton.21
KHDC3L is a second gene responsible for RHMs and is mutated in
14% of patients who are negative for NLRP7mutations.9,22 So far, four
different pathogenic variants in KHDC3L have been reported in a total
of six patients. KHDC3L codes for a KH-domain containing protein,
of which another member, KHDC1B, has been shown to bind mRNA
and is believed to play a role in the regulation of their translation
during oocyte maturation.23
The closest NLRP gene to NLRP7 is NLRP2, which is located 25-kb
distal to NLRP7 on human chromosome 19q13.4 in a head-to-head
orientation. NLRP7 does not have rodent or bovine orthologues and
is believed to have originated from a common NLRP2/7 ancestor
in primates.24
In this study, we report 11 novel protein-truncating variants
in NLRP7, of which five are large deletions. We characterized the
effects of four variants at the transcriptional level. We demonstrate
that six of the large deletion breakpoints occurred in intron 5 and
eight of the nine large deletions reported so far in NLRP7 may have
been mediated by Alu repeats and microhomology of 16-bp to 44-bp.
Our analysis demonstrates that human NLRP7 is highly rich in Alu
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repeats, which represent half of its intronic sequences, that may have
accumulated in the primate ancestor of NLRP2/7 before its duplication
into two distinct genes, NLRP2 and NLRP7.
MATERIALS AND METHODS
Patients
Patients included in this study were referred to our laboratories at the Research
Institute of the McGill University Health Centre, the ‘Laboratoire de génétique
des maladies rares et autoinflammatoires’, or the Genetics Department of the
Shiraz University of Medical Sciences, for NLRP7 mutation analysis. All the
patients included in the mutation analysis were new with the exception
of patient 1424 and her two affected sisters, 1426 and 1428, who were
previously reported as being heterozygous for a 60-kb deletion encompass-
ing portions of NLRP7 and NLRP2.25 In the transcriptional analysis of the
consequences of the variants, two other patients, 1200 and 1074, whose
mutations were previously reported, were included.20 The reproductive
history of the new patients recapitulated in Table 1. The products of
conception (POCs) of the patients listed in Table 1 were not available for
analysis with the exception of one molar tissue from patient 1428 that was
genotyped by our group and found diploid biparental confirming therefore
its previously reported genotype.25 All patients had RHMs with the
exception of patient 1291 who had four spontaneous abortions (SAs),
of which two were found triploid by karyotype analysis. Her products
of conception were not available for us for histopathological review and
genotyping, but were analyzed as part of the patient clinical care. One of her
triploid products of conception was genotyped by microsatellite DNA
markers and reported to be digynic. Her two other SAs were found diploid,
one with trisomy 9 and one with monosomy X (Table 1).
Mutation analysis and characterization of the deletions
NLRP7 mutation analysis was performed as previously described by PCR
amplification of the 11 exons of NLRP7 from genomic DNA followed by Sanger
sequencing of the PCR products in the two directions.8 Various other strategies
were performed to identify the exact variants in patients with suspected
deletions. These strategies included the design of additional primers for various
genomic regions, genotyping of NLRP7 fragments containing known single
nucleotide polymorphisms (SNPs) in all family members and establishment
of the haplotypes, regular and long range PCR, and genomic DNA dosage by
quantitative real-time PCR. The primer pairs that allowed the amplification of
the junction fragment for each of the described large deletions are provided in
Supplementary Table S1. Variants are described with reference to the following
transcript, NM_001127255.1, protein NP_001120727.1 and genomic sequence
NG_008056.1. Variant numbering starts with the initiation codon. All variants
detected have been deposited in the Leiden Open Variation Database (http://
databases.lovd.nl/shared/genes/NLRP7) (patient IDs 00054739-00054741,
00054760-00054768 and 00054773-00054779) and INFEVERS (http://fmf.igh.
cnrs.fr/ISSAID/infevers/). Exons are numbered as previously described in
Messaed et al.26
Quantitative real time PCR
Quantitative real time PCR to define the deletions in patients 1359 and 1424 was
performed using Quantifast SYBR-green PCR kit (Qiagen, Toronto, ON, Canada)
on 25-ng of genomic DNA. Each sample was tested in duplicates using the Bio-Rad
Miniopticon Real Time PCR system (Bio-Rad Laboratories, Mississauga, ON,
Canada) and analyzed using the Opticon Monitor software (Bio-Rad Laboratories).
The comparative CT method (ΔΔCT method) was used for relative quantification,
and data was normalized against an endogenous control sequence, exon 11 of
NLRP7 in patient 1359 and exon 8 of NLRP7 in patient 1424, both of which have
two normal copies documented by their heterozygous status for SNPs within the
amplicons that amplify these exons. Melting curve analysis was also done to verify
PCR specificity.
Reverse transcription PCR
Reverse transcription followed by PCR (RT-PCR) was performed on RNA
extracted from Epstein-Barr virus (EBV) transformed cells of patients 1074,
1200, 1243, 1291 and 1341 using Trizol (Invitrogen, Carlsbad, CA, USA) and
verified by electrophoresis. cDNA was synthesized using a reverse transcription
kit (Life Technologies, Thermo Scientific, Carlsbad, CA, USA). PCR after
reverse transcription was performed using primers located in exons 5 and 7
of NLRP7 for patients 1291 and 1200, primers from exons 9 and 11 for patients
1074 and 1243 and various primers located in exons 5 to 11 for patient 1341.
The amplified fragments were separated on 1.5% agarose gel, purified using
QIAquick PCR purification kit (Qiagen, Toronto, ON, Canada) and sequenced
using Sanger sequencing. To document the absence of NLRP7 transcripts
in patient 1341, primers from exons 5 and 7 of ZNF28 gene were used
in combination with the various NLRP7 primers in the same reaction as
technical positive control for the quality and quantity of RNA and the success
of the RT-PCR reactions. The various primers used in RT-PCR are provided in
Supplementary Table S2.
RESULTS
Identification of 11 novel protein truncating variants including five
large deletions
NLRP7 mutation analysis was performed by PCR amplification of all
exons from genomic DNA of 12 unrelated patients and direct
sequencing of the PCR products. The identified variants are listed in
Table 1 and some of them are shown in (Supplementary Figure S1).
These variants include two previously reported missense variants,
a previously reported splice variant, a new splice variant, two
novel single nucleotide substitutions leading to stop codons, two small
duplications (one previously reported and one novel), two small
deletions, and five large deletions. All patients were either homozygous
for one, or compound heterozygous for two, potentially pathogenic
variants with the exception of one patient, 1291, who had a small
deletion in a heterozygous state and no other variants that are believed
to be pathogenic. The variant found in this patient deletes six
nucleotides from intron 5 and the first three nucleotides of exon 6,
c.2130-6_2132del.
In patient 6202, regular PCR primers designed to amplify exon
6 did not yield any DNA amplification and suggested the presence of
a homozygous deletion. Other primers were designed and allowed the
amplification of a fragment overlapping the junction (Supplementary
Table S1). The sequencing of this fragment revealed the presence of
a 1219-bp deletion, c.2130-266_2300+782del, in a homozygous state.
Similarly, in patients P120 and her affected sister (P140), no
amplifications were obtained with primers designed to amplify exons
1–5. A series of primers, mapping around the suspected deleted region
were used in PCR to amplify the junction fragment that was
sequenced (Supplementary Table S1) and the analysis of its sequence
defined the deletion at the nucleotide level as c.-3998_2130-668del.
In patient 1341, no PCR fragments were amplified with the
primers for exons 2–6. We designed new primers and performed
primer walking using regular and long range PCR amplification on
the genomic DNA of the patient. This resulted in the amplification
of an ~ 1-kb fragment only in the patient, but not in controls
(Supplementary Table 1 and Supplementary Figure S2). Sequencing
this fragment and the analysis of its sequence revealed a 5041-bp
deletion extending from introns 1 to 5 and defined the deletion at
the nucleotide level to c.-39-231_2130-510del. This abnormal 1-kb
fragment overlapping the deletion was also amplified from DNA of the
two parents of the patient. We note that the size of the normal
fragment that does not contain the deletion is ~ 6-kb and was not
amplified on DNA from the parents of the patient or the controls
under our experimental conditions (Supplementary Figure S2).
Patients 1424, 1426 and 1428 are sisters and were previously
reported as carriers of a 60-kb deletion eliminating substantial
portions of NLRP2 and NLRP7 in a heterozygous state and with
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no other NLRP7 pathogenic variants.25 NLRP7 sequencing on DNA
from patient 1424 revealed a previously reported mutation, c.2571dup,
p.(Ile858Hisfs*11) in a heterozygous state. To define accurately the
deletion, we sequenced NLRP7 amplicons containing common SNPs
in all family members, genotyped additional SNPs in the family,
established the haplotypes and used quantitative real-time PCR
to define the 5’ breakpoint of the deletion close to NLRP7 exon 1
(Supplementary Figure S2) and the 3’ breakpoint close to NLRP7
intron 5. Using primers flanking the deletion, we amplified a fragment
of ~ 1.6-kb in the patient but not in controls (Supplementary Table S1).
Sanger sequencing defined the deletion at the nucleotide level to
c.-40+251_2130-681del (Table 1). The two protein truncating variants
are most likely pathogenic and segregated from the two parents to the
three affected sisters.
Patient 1359 was found homozygous for a previously reported
missense mutation, p.(Leu750Val) that was present only in her father
in a heterozygous state, but not in her mother. This raised the
possibility that the patient is hemizygous for the fragment containing
p.(Leu750Val). We then performed a high density SNP microarray
using Cytoscan HD (Affymetrix, Santa Carla, CA, USA), which
suggested that the patient is heterozygous for a deletion spanning
from introns 5 to 10 (Supplementary Figure S2). Sequencing of
NLRP7 amplicons containing common SNPs in all family members,
as well as genotyping additional SNPs from the region, haplotype
establishment, and genomic DNA dosage analysis using quantitative
real-time PCR using various genomic primers defined the 5’ break-
point to ~ 13-kb upstream of exon 1 and the 3’ breakpoint to intron
10. We then amplified the junction fragment in the patient, sequenced
it and defined the deletion at the nucleotide level to c.-13413_2982-
344del (Table 1). Because this deletion was not detected by PCR
amplification of the 11 NLRP7 exons from genomic DNA, we checked
by PCR for its presence in three other unrelated patients of the same
ethnic group to that of patient 1359 (Mexican origin), and in which
homozygosity for a mutation in NLRP7 was detected but the parents
Figure 1 Transcriptional characterization of four NLRP7 variants using RT-PCR on RNA from EBV-transformed patient cells. Red arrows denote missing or
abnormal fragments observed only in the patients. (a) RT-PCR on RNA from patient 1341 showing complete loss of NLRP7 transcripts using various
combinations of primers located in exons 5–11. Primers from exons 5 and 7 of ZNF28 gene were used in combination with those of NLRP7 as positive
controls for the RT-PCR. (b) RT-PCR on RNA from patient 1291 with a 9-bp deletion removing the invariant splice acceptor sites of exon 6 showing the
deletion of exon 6 from the cDNA. (c) RT-PCR on RNA from patient 1200 with an invariant splice acceptor site variant showing the loss of exon 6.
(d) RT-PCR on RNA from patients 1074 and 1243 (e) with the same variant affecting the invariant splice donor of exon 9. This variant leads to one common
abnormal fragment of 673-bp in the two patients resulting from the insertion of 162-bp of intron 9 between exons 9 and 10. In patient 1243, we observed
other faint fragments due to minor aberrant splicing, of them a fragment smaller than 673-bp is shown in this figure and is indicated by a red arrow.
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were not available for DNA testing. This analysis did not detect the
junction fragment in any of the three unrelated patients.
Analysis of the effects of four variants on NLRP7 transcription
The 5041-bp deletion identified in patient 1341, c.-39-231_2130-
510del, is the first reported homozygous deletion in NLRP7 that
removes the transcription start site (+1). To analyze its effect on the
gene transcription, we performed reverse transcription followed
by PCR on RNA extracted from EBV–transformed lymphoblastoid
cell lines from the patient with three combinations of primers that
amplify three cDNA fragments from exons 5 to 11 (Figure 1).
However, no cDNA fragments were amplified with the three
combinations of primers demonstrating the complete absence of
NLRP7 transcripts in the cell line from this patient.
Patient 1291 has a novel heterozygous 9-bp deletion that deletes the
splice acceptor of exon 6, in which we previously reported an invariant
splice site mutation, c.2130-2A4G, in a heterozygous state in patient
1200.20 To determine the effects of these two variants on the splicing
of exon 6, we performed RT-PCR on RNA from EBV–transformed
cells from the two patients, 1291 and 1200. This revealed the presence
of a normal (298-bp) and an abnormal shorter cDNA fragments
(127-bp) in the two patients (Figure 1). Purification of the short
fragments from the agarose gel and their sequencing revealed their
identical sequences and their lack of exon 6, presumably due to the
splicing variants (Figure 1).
We also assessed the effects of a previously reported splice variant
that affects the invariant splice donor site of exon 9, c.2810+2T4G,
in two patients, 1074 and 1243. We found that this variant leads
to different splicing in the two patients. In patient 1074, this variant
led to an abnormal cDNA fragment of 673-bp that contains the first
162-bp of intron 9 and is expected to result in an in-frame insertion
of 54 amino acids in the protein. In the second patient, 1243, the same
variant yielded, in addition to the 673-bp fragment, to another smaller
cDNA fragment of ~ 650-bp (Figure 1) and to some other faint
fragments larger than 673-bp (data not shown) that could not
be cloned and were not observed in more than 10 control subjects.
Eight Alu mediated large deletions and rearrangements in NLRP7
For all the five novel large deletions described in this study, the
breakpoints were within Alu elements and were found flanked
Figure 2 Characterization of five large NLRP7 deletions identified in this study and schematic representation of the Alu elements at the breakpoints.
The microhomology sequences surrounding the deletions are shown in capital letters and the unique sequences on each side of the microhomology
sequences are shown in small letters. Red letters indicate differences between the two microhomology elements or the flanking sequences. Dashed red lines
delimit the deletions. The orientation of the Alu repeats is indicated by arrows above each repeat.
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by microhomology over 16-bp to 44-bp on both sides of the
breakpoints with one of the microhomology element being completely
or partially removed by the deletion (Figure 2). In addition, the same
microhomology element was present in more than one region within
the genomic structure of NLRP7. For instance, the microhomology
element of 37-bp flanking the deletion in patient 6202 is also involved
in a previously reported variant, c.2130-312_2300+736del14 and the
microhomology element present at the 5’ and 3’ breakpoints of the
deletion in patient 1424 is also present at the breakpoints of
a previously reported deletion by Kou et al.10 We therefore analyzed
the whole genomic structure of NLRP7, a total of 25,991-bp (starting
1-kb upstream of exon 1 to 1-kb downstream of exon 11) (hg19 at
https://genome.ucsc.edu/) for repetitive elements using CENSOR,27
a publicly available software that screens query sequences against
a reference collection of repeats (http://www.girinst.org/censor/). This
analysis led to the identification of Alu repetitive elements surrounding
all the five deletions reported in this study (Figure 2) and the three
previously reported ones10,14 (Figure 3). We also found that NLRP7 is
highly rich in Alu repeat elements, which account for ~ 48% of all its
intronic sequences with introns 2, 5 and 10 being the richest with Alu
content of 70%, 66% and 60%, respectively (Figure 3). In addition, for
four of the novel deletions, their 3’ breakpoints were within a 1-kb
interval in intron 5, which includes also the breakpoints of two
previously reported deletions and rearrangements10,14,28 and define
a hotspot of Alu instability, deletions and rearrangements (Figure 3).
DISCUSSION
Here we describe eleven novel protein truncating variants in NLRP7 in
unrelated patients, three from familial and eight from simplex cases.
All patients had RHMs and were found to have two defective alleles with
the exception of one patient, 1291, who had four SAs and a single
heterozygous 9-bp deletion. The presence of a single NLRP7 protein
truncating variant in this patient with four SAs supports previous
observations by our group26 and others29,30 about the involvement of
NLRP7 in the genetic susceptibility for recurrent SAs in a minority of cases.
We also characterized the consequences of four different variants
on NLRP7 transcription. We demonstrated the absence of NLRP7
transcripts in EBV-transformed cells from patient 1341 with a
homozygous large deletion that removes 5041-bp including the
transcription start site. This patient is therefore the first with
Figure 3 Recapitulation of all NLRP7 large deletions and distribution of Alu elements in its intronic sequences. To date, eight Alu-repeat mediated deletions
and rearrangements in NLRP7 have been described. Colored boxes refer to specific Alu subfamilies, each with a specific color. Novel and previously reported
mutations are in red and black, respectively. Arrows on the top of the colored boxes indicate the orientation of the Alu elements. Six of the 16 deletions and
rearrangement breakpoints occurred in intron 5 and define a hotspot of Alu instability, deletions, and rearrangements shown in a rectangle. N, stands for
number; seq. stands for sequences. % of Alu seq, indicates the percentage of the length of Alu sequences in each intron divided by the total length of the
sequence of each intron.
Figure 4 Alu distribution in human NLRP genes. For all genes, the genomic
structures were downloaded from the UCSC Genome browser (hg19) and
each included 1-kb upstream the first exon and 1-kb downstream of the last
exon. The presence of Alu repeats was investigated using CENSOR (http://
www.girinst.org/censor/). The percentage of Alu sequences in each gene
represents the total length of its Alu sequences over the length of its
genomic structure. We note that Alu elements were mostly found in introns,
which is in agreement with known data about most Alu sequences.
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a demonstrated complete absence of NLRP7 transcripts. The fact that
she is in good health besides her reproductive problem strengthens
current knowledge about the main requirement of NLRP7 for female
reproduction. In two other patients, 1291 and 1200, we demonstrated
that their different splice variants, c.2130-6_2132del and c.2130-
2A4G, lead to the same splice consequence and skipping of exon 6
from the mature RNA. We note that the skipping of exon 6 does not
disrupt the open reading frame but is expected to delete 56 amino
acids located between the second and the third leucine-rich-repeats
and part of the third leucine-rich-repeats. In two other patients, 1074
(reported previously8) and 1243, we found that the mutation of the
acceptor splice site of exon 9, c.2810+2T4G, activates a new splice
site that does not have a canonical GT invariant donor and leads
mainly to an in-frame insertion of 162-bp between exons 9 and 10.
Other minor aberrant splice isoforms were also observed only in
patient 1243 and could be due to the intrinsic degenerate nature of the
activated non-canonical splice site. Our data on the consequences
of this splice variant in patient 1074 are in agreement with those
observed by Kou et al.10 on the same splice variant.
To date and including this study, 59 distinct pathogenic variants in
recessive state have been reported in NLRP7, of which four previously
reported large deletions10,14,28 and five novel ones. Analysis of the
sequences flanking the nine deletions showed that seven have their two
breakpoints within Alu elements, one has only one breakpoint within
an Alu element,28 and the remaining does not have any breakpoint in
Alu elements, but in exonic sequences (in exon 4).14 Careful analysis
of the deletions revealed that seven of them have microhomology of 16
to 44 nucleotides adjacent to their 5’ and 3’ breakpoints. In the eight
large deletions, the involved microhomology repeats, as well as the Alu
elements to which they belong, have the same orientations. Among 15
breakpoints located within Alu elements, 11 occurred in the left arms
of the Alu elements, two occurred in the right arms and two in the
middle of the Alu elements. In summary, of the 15 breakpoints within
Alu elements, one occurred in intron 10, two several kilobases
upstream of exon 1, three in intron 1, three in intron 6 and six in
intron 5, of which three in the same AluY element. These six different
deletions in unrelated subjects define a hotspot of Alu instability and
deletions in intron 5 (Figure 3).
Because all the intronic breakpoints of the large NLRP7 deletions
occurred within Alu repeats, we screened NLRP7 genomic sequence
for Alu repeat elements. This analysis revealed that ~ 48% of the total
NLRP7 genomic structure (25,997-bp) is occupied by Alu sequences,
which represent one Alu insertion every 450-bp, and is much higher
than the known Alu density in the human genome (one insertion per
3,000-bp).31–33 Alu elements are well-known to be primates specific34
and so is NLRP7, which is believed to have duplicated from a NLRP2/7
ancestor in primates.24 To better understand NLRP7 evolution, we
looked at the Alu content of human NLRP2 and found it, similar to
NLRP7, highly rich in Alu elements. Indeed, NLRP2 and NLRP7 along
with NLRP12 are the richest NLRPs in Alu elements (Figure 4). In
addition, the human NLRP2 and NLRP7 display the same percentages
of various Alu subfamilies similar to their orthologues in chimpanzees,
gorillas, orangutans, rhesus, baboon and marmoset (data not shown)
suggesting that Alu insertion in primates NLRP2 and NLRP7 occurred
in their common NLRP2/7 ancestor before its duplication into two
genes. Because of the known role of Alu elements in segmental
duplications on many chromosomes,25,28 it is possible that Alu
insertion and expansion in the primate NLRP2/7 may have mediated,
or helped in, its duplication in two distinct genes.
Alu elements are the most abundant and successful short inter-
spersed elements found in the human genome. Alu elements are
estimated to contribute to 0.075% of human mutations35 and form
a major part of extensive genomic structural variation.33,36,37 There are
multiple factors that predispose Alu elements to recombination and
include, the number of Alu elements in a chromosome or a region,
the close proximity of the Alu elements to each other, the high GC
content of their sequences, and the high sequence similarity between
the different Alu subfamilies (70-100%).33 Including the current study,
the total number of distinct NLRP7 mutations is 59 of which eight
(13.5%) are mediated by Alu recombination. Therefore, Alu mediated
mutations seem to be 180-times more frequent in NLRP7 than
the average of all known human mutations. This suggests that the
genomic architecture of NLRP7 gene may be prone to the occurrence
of Alu-mediated deletions and rearrangements that may not be
detected by Sanger sequencing or next generation exome sequencing.
Our data call for more attention in reporting DNA testing in patients
with apparently homozygous NLRP7 mutations, mainly when the
parents are not available for testing. In such patients, compound
heterozygous mutations for one detectable mutation by Sanger
sequencing and a large deletion may appear as homozygous for the
detectable mutation and consequently lead to an inaccurate molecular
diagnosis and reproductive genetic counseling.
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